Novo Nordisk Scraps Rare-Disease Plant and Unleashes High-Dose Data to Fortify GLP-1 Empire
Novo Nordisk shifts focus to weight-loss drugs, converting a rare-disease factory into GLP-1 warehousing. Q1 earnings beat estimates…
Browsing Tag